FDMT
4D Molecular Therapeutics, Inc.Healthcare · $748M market cap
Verdict
We can't put a fair value on FDMT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow FDMT
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases, 1 sale worth $8K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works